Restoring Lives
One Story At A Time
We are Assertio — an assertive, energetic, and empathetic pharmaceutical company built around the mission of advancing patient care. Formerly known as Depomed, we have transformed our company with a current focus on three FDA-approved products in our core areas of neurology, orphan, and specialty medicines, as we continue to identify, license, and develop new products that offer enhanced options for patients who may be underserved by existing therapies. More
In the News
April 8, 2020
Assertio Therapeutics Announces Completion and Final Results of the Offer to Purchase All of Its Issued and Outstanding 2.50% Senior Convertible Notes due 2021 and 5.00% Senior Convertible Notes due 2024Read More
March 16, 2020
Assertio Therapeutics Agrees to Merge with Zyla Life Sciences to Create Synergistic Portfolio of Neurology and Non-Opioid Pain ProductsRead More
March 11, 2020
Assertio Therapeutics Announces Offer to Purchase All of Its Issued and Outstanding 2.50% Senior Convertible Notes Due 2021 and 5.00% Senior Convertible Notes Due 2024Read More